- Home
- RNXT vs AUC Comparison
RNXT vs AUC Comparison
Compare RNXT & AUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | AUC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4M | 89.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RNXT | AUC |
|---|---|---|
| Price | $1.17 | $6.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 385.0K | 18.7K |
| Earning Date | 11-05-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $243.48 | N/A |
| Revenue Next Year | $196.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $5.00 |
| 52 Week High | $2.59 | $9.40 |
Technical Indicators
Market Signals| Indicator | RNXT | AUC |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 46.84 |
| Support Level | $0.83 | $5.67 |
| Resistance Level | $1.30 | $8.00 |
| Average True Range (ATR) | 0.16 | 1.20 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 43.28 | 51.83 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About AUC ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.